This is likely due to the fact that celecoxib inhibits COX-2-mediated PGE2 synthesis evidenced by the reduced arthritis index, but does not inhibit NF-κB, an important mediator for bone and cartilage degradation. This evidence concerns the gene NFKB1 and arthritic joint disease.